Related references
Note: Only part of the references are listed.Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Alok A. Khorana et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
M. Ducreux et al.
ANNALS OF ONCOLOGY (2015)
CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer
Melania Zauri et al.
NATURE (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients
Cindy Serdjebi et al.
PLOS ONE (2015)
Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review
Erkut Borazanci et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2015)
Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen
Cindy Serdjebi et al.
PHARMACOGENOMICS (2013)
nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
Kristopher K. Frese et al.
CANCER DISCOVERY (2012)
Adenosquamous Versus Adenocarcinoma of the Pancreas: A Population-Based Outcomes Analysis
Matthew Harold G. Katz et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2011)
Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer
Hongmei Zeng et al.
PANCREAS (2011)
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial
John P. Neoptolemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients
H. Ueno et al.
BRITISH JOURNAL OF CANCER (2009)
Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results
Cedric Mercier et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Pharmacokinetics of gemcitabine in Japanese cancer patients: The impact of a cytidine deaminase polymorphism
Emiko Sugiyama et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma
C Bengala et al.
BRITISH JOURNAL OF CANCER (2005)
Forced expression of cytidine deaminase confers sensitivity to capecitabine
T Morita et al.
ONCOLOGY (2003)
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer:: a randomised controlled trial
JP Neoptolemos et al.
LANCET (2001)
Share Paper
